Treatment of retinitis pigmentosa with human umbilical cord cells
First Claim
Patent Images
1. A method of treating a patient having retinitis pigmentosa, the method comprising administering cells isolated from a human postpartum umbilical cord to the interior of the patient'"'"'s eye, in an amount effective to treat the retinitis pigmentosa, wherein the cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and have the following characteristics:
- a) potential for at least 40 doublings in culture;
b) attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin;
c) production of vimentin and alpha-smooth muscle actin;
d) production of CD10, CD13, CD44, CD73, HLA-A,B,C, and CD90;
e) increased expression of endogenous genes encoding interleukin 8 and reticulon 1 relative to endogenous expression of interleukin 8 and reticulon 1 in a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell; and
f) lack of production of CD31, CD34, CD45, CD117, and CD141.
10 Assignments
0 Petitions
Accused Products
Abstract
Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.
344 Citations
6 Claims
-
1. A method of treating a patient having retinitis pigmentosa, the method comprising administering cells isolated from a human postpartum umbilical cord to the interior of the patient'"'"'s eye, in an amount effective to treat the retinitis pigmentosa, wherein the cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and have the following characteristics:
-
a) potential for at least 40 doublings in culture; b) attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin; c) production of vimentin and alpha-smooth muscle actin; d) production of CD10, CD13, CD44, CD73, HLA-A,B,C, and CD90; e) increased expression of endogenous genes encoding interleukin 8 and reticulon 1 relative to endogenous expression of interleukin 8 and reticulon 1 in a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell; and f) lack of production of CD31, CD34, CD45, CD117, and CD141. - View Dependent Claims (2, 3, 4, 5, 6)
-
Specification